Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2018Clinical Infectious Diseases

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJason M. PogueRBRobert A. BonomoKKKeith S. Kaye

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pogue et al. (2018) studied this question.

synapsesocial.com/papers/6aa024afd15c5dee7bbac37fhttps://doi.org/10.1093/cid/ciy576
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mutations in<i>bla</i><sub>KPC-3</sub>That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases2017 · 194 citations
  2. 2Activity of ceftazidime/avibactam against isogenic strains of <i>Escherichia coli</i> containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop2015 · 137 citations
  3. 3<i>In Vitro</i> Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase2015 · 167 citations
  4. 4Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection2017 · 158 citations
  5. 5Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae2017 · 662 citations